Search Results - "GARRETT, Chris R"

Phase I Trial of Poly-l-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies by HOMSI, Jade, SIMON, George R, ANGIULI, Patrizia, EISENFELD, Amy, SULLIVAN, Daniel M, DAUD, Adil I, GARRETT, Chris R, SPRINGETT, Gregory, DE CONTI, Ronald, CHIAPPORI, Alberto A, MUNSTER, Pamela N, BURTON, Michelle K, STROMATT, Scott, ALLIEVI, Claudia

“…Purpose: CT-2106 is a 20( S )-camptothecin poly- l -glutamate conjugate. This linkage stabilizes the active lactone form of camptothecin and enhances aqueous…”
Get full text

Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer by Boasberg, Peter D., Redfern, Charles H., Daniels, Gregory A., Bodkin, David, Garrett, Chris R., Ricart, Alejandro D.

“…Purpose To assess further the tolerability and preliminary antitumor activity of PD-0325901 in previously treated patients with advanced melanoma, breast…”
Get full text

The metformin effect on survival in Middle Eastern patients (pts) with type II diabetes (DM) and colorectal cancer (CRC) by Al Omari, Amal, Abdelkaleq, Hadeel, Al-Hussaini, Maysa, Turfa, Rim, Awad, Nour, Hassan, Manal, Garrett, Chris R.

“…Abstract only…”
Get full text

Validation of the survival benefit from metformin use in patients with type 2 diabetes and colorectal cancer by Sahin, Ibrahim Halil, Hassabo, Hesham Mohamed, Shen, Yehua, Kee, Bryan K., Hassan, Manal, Garrett, Chris R.

“…Abstract only 462 Background: We previously reported improved overall survival (OS) associated with metformin usage in a retrospective study of type 2 diabetes…”
Get full text

Prevalence of recurrent thrombosis in cancer patients with isolated gonadal vein thrombosis: A retrospective study by Tanasanvimon, Suebpong, Garg, Naveen, Viswanathan, Chitra, Javle, Milind M., Truong, Mylene, Kaur, Harmeet, Garrett, Chris R.

“…Abstract only e19645 Background: The natural history of isolated gonadal vein thrombosis (GVT) occurring in cancer patients (pts) is not well described in the…”
Get full text

Outcomes in patients (pts) with colorectal cancer (CRC) treated with oxaliplatin-based chemotherapy (OC) following prior oxaliplatin exposure by Bhadkamkar, Nishin Anil, Sahin, Ibrahim Halil, Shen, Yehua, Hassabo, Hesham Mohamed, Kee, Bryan K., Hassan, Manal, Garrett, Chris R.

“…Abstract only 500 Background: Pts frequently treated with OC in the adjuvant, perioperative, or first-line setting for CRC may be retreated with oxaliplatin at…”
Get full text

Prognostic effect of angiotensin-converting-enzyme inhibitors in HCC patients treated with sorafenib by Abouelezz, Khaled, Kaseb, Ahmed Omar, Hassabo, Hesham Mohamed, Garrett, Chris R., Vauthey, Jean-Nicolas, Li, Donghui, Hassan, Manal

“…Abstract only 328 Background: Experimental studies indicated that angiotensin-converting-enzyme inhibitors (ACEs) or angiotensin receptor blockers (ARBs) has a…”
Get full text

Retrospective evaluation of Middle Eastern patients (pts) with type II diabetes mellitus (DM) and colorectal cancer (CRC): Validation of metformin effect on overall survival (OS) by Al Omari, Amal, Abdelkaleq, Hadeel, Al-Hussaini, Maysa, Turfa, Rim, Awad, Nour, Al Mutar, Salwan S., Hassabo, Hesham M., Sahin, Ibrahim Halil, Hassan, Manal, Garrett, Chris R.

“…Abstract only 478 Background: Epidemiologic data suggest that anti-DM medications may impact OS in CRC pts who have type 2 DM. Although type 2 DM and CRC are…”
Get full text

Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer by Lee, Michael Sangmin, Overman, Michael J., Maru, Dipen M., Jiang, Zhi-Qin, Manuel, Shanequa, Eng, Cathy, Kee, Bryan K., Fogelman, David R., Garrett, Chris R., Advani, Shailesh M, Vilar Sanchez, Eduardo, Shureiqi, Imad, Wolff, Robert A., Hamilton, Stanley R., Kopetz, Scott

“…Abstract only…”
Get full text

Predictors of clonal evolution in metastatic colorectal cancer patients by Morelli, M. Pia, Overman, Michael J., Kee, Bryan K., Vilar Sanchez, Eduardo, Morris, Van Karlyle, Fogelman, David R., Janku, Filip, Garrett, Chris R., Shureiqi, Imad, Raghav, Kanwal Pratap Singh, Eng, Cathy, Manuel, Shanequa, Wolff, Robert A., Eltoukhy, Helmy, Lanman, Richard Burnham, Talasaz, AmirAli, Kopetz, Scott

“…Abstract only…”
Get full text

Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment in refractory metastatic colorectal cancer patients by Morris, Van Karlyle, Morelli, M. Pia, Janku, Filip, Overman, Michael J., Kee, Bryan K., Fogelman, David R., Vilar Sanchez, Eduardo, Shureiqi, Imad, Garrett, Chris R., Raghav, Kanwal Pratap Singh, Eng, Cathy, Manuel, Shanequa, Wolff, Robert A., Eltoukhy, Helmy, Lanman, Richard Burnham, Talasaz, AmirAli, Kopetz, Scott

“…Abstract only…”
Get full text

Association between KRAS mutation and lung metastasis in advanced colorectal cancer by Pereira, Allan Andresson Lima, Rego, Juliana Florinda De Mendonga, Morris, Van Karlyle, Overman, Michael J., Eng, Cathy, Garrett, Chris R., Ferrarotto, Renata, Lee, Michael Sangmin, Jiang, Zhiqin, Hoff, Paulo Marcelo, Vauthey, Jean-Nicolas, Vilar Sanchez, Eduardo, Maru, Dipen M., Kopetz, Scott

“…Abstract only 494 Background: The role of KRAS status in the time-dependent pattern of metastasis in colorectal cancer (CRC) patients has been reported but not…”
Get full text

Effect of bevacizumab on rate of oxaliplatin-induced thrombocytopenia and splenomegaly by Raghav, Kanwal Pratap Singh, Kalil, Karime, Ferrarotto, Renata, George, Binsah, Eng, Cathy, Garrett, Chris R., Loyer, Evelyn, Hoff, Paulo, Charnsangavej, Chusilp, Kopetz, Scott, Overman, Michael J.

“…Abstract only 3544 Background: Oxaliplatin-based chemotherapy can cause hepatic sinusoidal injury (HSI) leading to portal hypertension. This results in splenic…”
Get full text

Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies by Morelli, M. Pia, Overman, Michael J., Dasari, Arvind, Kazmi, Syed Mohammad Ali, Vilar Sanchez, Eduardo, Eng, Cathy, Kee, Bryan K., Deaton, Laurel, Garrett, Chris R., Diehl, Frank, Angenendt, Philipp, Kopetz, Scott

“…Abstract only 3512 Background: Although KRAS and EGFR extracellular domain acquired mutations were detected in two small cohorts and correlated with acquired…”
Get full text

Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC) by Kopetz, Scott, Overman, Michael J., Chen, Ken, Lucio-Eterovic, Agda Karina, Kee, Bryan K., Fogelman, David R., Dasari, Arvind, Raghav, Kanwal Pratap Singh, Vilar Sanchez, Eduardo, Phillips, Jonathan, Shureiqi, Imad, Garrett, Chris R., Wolff, Robert A., Patel, Keyur, Aldape, Kenneth D., Luthra, Rajyalakshmi, Routbort, Mark, Maru, Dipen M., Meric-Bernstam, Funda, Eng, Cathy

“…Abstract only…”
Get full text

Rechallenge with anti-EGFR–based therapy in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response by Liu, Xiaochun, George, Goldy C., Tsimberidou, Apostolia Maria, Naing, Aung, Wheler, Jennifer J., Kopetz, Scott, Fu, Siqing, Piha-Paul, Sarina Anne, Eng, Cathy, Falchook, Gerald Steven, Janku, Filip, Garrett, Chris R., Karp, Daniel D., Kurzrock, Razelle, Zinner, Ralph, Raghav, Kanwal Pratap Singh, Subbiah, Vivek, Meric-Bernstam, Funda, Hong, David S., Overman, Michael J.

“…Abstract only…”
Get full text

Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience by Morris, Van Karlyle, Overman, Michael J., Kee, Bryan K., Fogelman, David R., Eng, Cathy, Dasari, Arvind, Shroff, Rachna T., Deaton, Laurel, Manuel, Shanequa, Garrett, Chris R., Vilar Sanchez, Eduardo, Dennis, Constance S., Shureiqi, Imad, Mills, Gordon B., Shaw, Kenna Rael, Hamilton, Stanley R., Wolff, Robert A., Meric-Bernstam, Funda, Maru, Dipen M., Kopetz, Scott

“…Abstract only…”
Get full text

Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastatic CRC patients by Morelli, M. Pia, Overman, Michael J., Vilar Sanchez, Eduardo, Morris, Van Karlyle, Shureiqi, Imad, Garrett, Chris R., Fogelman, David R., Raghav, Kanwal Pratap Singh, Kee, Bryan K., Deaton, Laurel, Eng, Cathy, Wolff, Robert A., Sebisanovic, Dragan, Siew, LaiMun, Zapanta, Aubrey, Mei, Gangwu, Schiller, Ben, Eltoukhy, Helmy, Talasaz, AmirAli, Kopetz, Scott

“…Abstract only…”
Get full text

Phase II study of EZN-2208 (PEG-SN38) with or without cetuximab in patients with metastatic colorectal cancer (CRC) by Goldberg, Richard M., Garrett, Chris R., Berkowitz, Noah C., Bekaii-Saab, Tanios S., Ryan, Theresa, Fisher, George A., Clive, Sally, Kavan, Petr, Shmueli, Einat, Buchbinder, Aby

“…Abstract only 448 Background: EZN-2208 is a water-soluble, parenterally-delivered PEGylated conjugate of SN38 that increases solubility, exposure, and apparent…”
Get full text

Systematic survey of therapeutic trials for metastatic colorectal cancer by Chen, Zhiyu, Overman, Michael J., Garrett, Chris R., Jiang, Zhi-Qin, Wolff, Robert A., Abbruzzese, James L., Eng, Cathy, Kopetz, Scott

“…Abstract only 523 Background: The FDA’s 2004 “Critical Path Initiative” encouraged novel clinical trials and incorporation of biomarker-based enrichment…”
Get full text